Compare Byrna Technologies Inc (BYRN) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Byrna Technologies Inc vs Novo Nordisk A/S — how do they compare? Byrna Technologies Inc trades at $4.3 (market cap $96.89M), while Novo Nordisk A/S trades at $45.88 (market cap $202.59B). The key difference: Novo Nordisk A/S is far larger — about 2090.9× Byrna Technologies Inc's market cap, and Novo Nordisk A/S pays a 3.87% dividend while Byrna Technologies Inc pays none. Which is the better fit depends on your goals.
| BYRN | NVO | |
|---|---|---|
Market Cap | $96.89M | $202.59B |
Sector | Technology | Health |
52-Week High | $27.63 | $63.98 |
52-Week Low | $3.18 | $35.29 |
Enterprise Value | $88.50M | $217.28B |
Dividend Yield | — | 3.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BYRN trades at $4.25, down 12.37% on the day, reflecting investor reaction to recent earnings misses and revenue declines. The stock shows a bullish technical signal with strong moving average support, but fundamentals are mixed with a negative net income margin of -3.39% and ROE of -6.3% for 2026. Recent management changes and strategic acquisitions aim to revitalize growth amid sales challenges highlighted in Q2 2026 results.
The outlook remains cautious due to execution risks in marketing turnaround and competitive pressures. Analyst consensus is 71% buy, but investors face volatility from ongoing investigations and weak quarterly performance. Upside depends on successful brand repositioning and retail expansion under new leadership.
Novo Nordisk (NVO) trades at $46.465, down 2.65% today, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.62, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights competitive pressures from Eli Lilly and mixed investor reactions to Q2 2026 results, despite an upwardly revised full-year outlook.
Outlook remains positive due to robust GLP-1 drug demand and profitability, but risks include pricing pressure and competition. Analysts are predominantly bullish (57.9% buy ratings), supporting a favorable long-term view despite near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Byrna Technologies Inc
Byrna Technologies specializes in less-lethal personal security devices. It develops and manufactures innovative handheld launchers and projectiles designed for self-defense, law enforcement, and private security use.
Read more on BYRN →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
